Highlights 1) AID associated to MDS/CMML is difficult to manage 2) Azacitidine can improve the control of AID associated with MDS/CMML.
Introduction
Autoimmune disorders are observed in 10 to 30% of MDS and CMML, typically diagnosed concomitantly or shortly before or after MDS/CMML [1] .
Most common AID associated with MDS/CMML include relapsing polychondritis, vasculitis, non-erosive and seronegative arthritis [2, 3] and Sweet's syndrome [4] . While AID associated with MDS/CMML usually respond to corticosteroids [2] , many patients remain steroid dependent or resistant, requiring additional IST, a situation which increases the risk of severe cytopenias and infections in the context of MDS/CMML [1] .
Azacitidine significantly improves survival in higher risk MDS [5] and in myelodysplastic type CMML [6, 7] and is also approved outside Europe for the treatment of lower risk MDS. Seven patients with MDS/CMML and AID treated with Azacitidine have been reported to our knowledge [8] [9] [10] [11] .
Methods
We retrospectively analyzed the efficacy of Azacitidine in MDS/CMML patients with concomitant AID seen between 2007 and May 2014 in registries of the Société Nationale Française de Médecine Interne (SNFMI) and of the Groupe Francophone des Myélodysplasies. The SNFMI registry included 123 MDS/CMML patients with AID in 26 centres) [13] , while the GFM registry included 4202 MDS/CMML in 30 centres of whom 80 also had documented AID. The GFM registry has been so far the basis for many publications of the GFM or that included the GFM [14] [15] [16] .
Inclusion criteria for the present study were (i) complete or atypical AID according to usual international criteria [17] , (ii) MDS or non-proliferative CMML (ie with WBC<13G/L), classified according to WHO 2008 criteria [18] but also including patients with up to 30% marrow blasts, (iii) treatment with at least one cycle of Azacitidine.
Patients were excluded if AID were caused by infectious disease, AID were in remission without steroids or IST at Azacitidine onset, or if IST was administered more than 12 months before diagnosis of MDS, suggesting MDS secondary to IST.
Complete/ partial remission (CR/PR) of AID after Azacitidine were defined by complete/partial disappearance of clinical or biological signs with stable dose or decrease/discontinuation of steroids or IST, as previously defined [2] . Hematological response to Azacitidine was classified according to IWG 2006 criteria [18] . 
Results
Among patients with both MDS/CMML and AID included in the 2 registries, twenty eight patients had received Azacitidine (flow chart in figure 1 ). Six were excluded, because AID were in remission without IST at Azacitidine onset (n=2), of inadequate follow-up (n=3) and as vasculitis was post-infectious (n=1). Median age of the 22 remaining patients was 70 years (range 41-84), including 6 females and 16 males (73%). (Table 1) Diagnosis of MDS/CMML preceded AID diagnosis (n=8; by a median of 17 months), was concomitant with (n=7) or followed AID diagnosis (n=7; by a median of 20 months).
AID and MDS characteristics
At MDS/CMML diagnosis, 14 patients had low or int-1 IPSS and 8 had int-2 or high IPSS. The 2 cases of CMML with WBC below 13G/L were classifiable by IPSS. 
AID features at Azacitidine onset
At Azacitidine onset, AID was still active (n=15), in PR (n=5) and in CR (n= 2).
Nineteen patients still reported clinical symptoms related to AID including asthenia (n=17), weight loss (n=8), fever >38.5°C (n=8), rheumatologic signs (n=15), skin involvement (n=10), oral aphtosis (n=4) ( Table 1 ). Twenty (91%) patients were receiving steroids (median: 23 mg/day) for a median duration of 11 months (range 1-101) with no efficacy (n=13), partial efficacy (n=5) and full efficacy on AID (n=2). In patients where steroids were ineffective, they were however generally continued to avoid AID flare. The median duration of steroid use, in the 18 good responders on AID, was 16 months (range 1-101) versus 9 (range 8-9) in the non-responders.
Thirteen patients were non-responders to IST and 11 received concomitant treatment with IST and steroids: without efficacy in 7 patients, partial efficacy in 2 and full efficacy in 2 ( Table 1) . Onset of IST preceded that of Azacitidine by a median of 7 months (range 1-50); the 3 patients who did not have a good response on AID did not receive IST.
Median interval between MDS/CMML diagnosis and Azacitidine onset was 9 months (range 1-93). Azacitidine was the first-line treatment of MDS/CMML in 16 patients (73%) and was in 6 patients preceded by lenalidomide (n=2), hydroxyurea (n=2), idarubicin (n=1) and low dose cytarabine (n=1), treatments to which AID had not responded in any patient.
MDS features at Azacitidine onset
At Azacitidine onset, 11 patients had int-2 or high IPSS, and Azacitidine was used according to the drug label in EU; in the 11 low or int-1 IPSS, reasons to start Azacitidine were RBC transfusion dependence or severe thrombocytopenia in 8 patients (6 of whom also had AID flare) and AID flare alone in 3 patients (Table1).
AID response
Patients received a median of 6 cycles of Azacitidine (range 3-14). CR of AID was observed in 16 patients (73%), PR in 3 cases (14%) and no effect or worsening of AID in 3 cases (14%). All responses were observed within 3 cycles, but 8 PR after 3 cycles became CR after 6 months. In the 3 patients treated with Azacitidine for AID flare alone, one achieved CR, one PR and the last patient did not respond. Steroids were tapered from 40 mg/day to 16 mg/day in one patient and IST was discontinued in another patient.
Median prednisone dose was reduced from 23 mg/day to 9 mg/day (p=0.001), including prednisone discontinuation in 3 patients (14%) and dose reduction in 14 patients (64%) (Table1). IST discontinuation was possible in 7 patients (32%). In the 9 steroid-dependent or resistant patients, median prednisone dose was decreased from 50mg/day to 5mg/day (p=0.01) and prednisone discontinuation was possible in 3 patients. IST discontinuation was possible in the 3 patients who received them.
After Azacitidine treatment, median CRP levels decreased from 40 (range 0-300) to 15 mg/L (range 0-146) (p=0.28).
MDS response
Response of MDS/CMML to Azacitidine was seen in 12 patients (55%), including CR in 9 patients (41%), PR in 1, stable disease with erythroid response in 1, marrow CR in 1, stable disease without response of cytopenias in 8 and progression in 2.
MDS/CMML and AID evolution were concordant in 13 cases (59%): both improved (n=11) or worsened (n=2). In the other patients, AID improved while MDS worsened (n=8) and vice versa (n=1).
Side effects/ Evolution
Adverse events occurring during Azacitidine treatment included: 9 grade 2-3 infections (6 of them occurred in Int-2 or high IPSS patients), 1 fatal CNS bleeding, 1 deep vein thrombosis, 1 Interstitial lung disease.
Only 3 relapses of AID were seen after 3, 19 and 19 months respectively, and 5 patients had response duration ≥ 12 months, but median follow-up from response to Azacitidine was only 8 months (Table1).
Seven patients (32%) progressed to AML and 10 patients (45%; including 80% of IPSS int-2 and high risk patients) had died, from CNS bleeding (n=3), severe infection (n=5), progression in AML (n=1) and myocardial infarction (n=1). Among the 10 patients who died, 6 had progressed to AML. Severe infections were more frequently linked to AML progression than to Azacitidine. Median survival from Azacitidine onset was 16 months in IPSS high or int-2 MDS, and was not reached in IPSS low and int-1 MDS.
Discussion
Azacitidine improved clinical signs of AID in 86% of the cases (73%CR, 14%PR) in patients with MDS/CMML.Azacitidine also allowed to reduce the steroid dose in 64% of the patients and discontinuation of other IST in 32% of them.
In patient n°5, Azacitidine allowed to discontinue both MMF and hydroxychloroquine without having an AID flare. In patient n°10, prolonged clinical and biological complete response was maintained under Azacitidine without requirement of new IST or steroids.
In the only 7 cases of AID with MDS/CMML treated with Azacitidine published so far to our knowledge, 6 were refractory to steroids and/or IST and 4 had higher risk IPSS. MDS and AID evolution were concordant in six cases ( Table 2 ) [8] [9] [10] [11] .
In our series, all responses of AID to Azacitidine were seen by the third cycle, although about one third of responses improved and became complete between 3 and 6 cycles. Furthermore, although less than 50% of the patients received more than 6 cycles of Azacitidine, only 3 relapses were observed (but with a median follow-up from response of AID to Azacitidine of only 8 months).
Most of the MDS/CMML included in the present study required some treatment because of high or int-2 IPSS in 11 cases, RBC transfusion dependence or severe thrombocytopenia in 8 cases. In the last 3 patients, however AID flare refractory to IST and/or high dose steroids was the only reason to start Azacitidine.
The concordant evolution of AID and MDS/CMML we observed in 59% of the cases further supports a pathophysiological link between MDS/CMML and AID. However, it often remains unclear, in MDS/CMML associated with AID, which of the 2 diseases is the cause and which is the consequence. While immunological defects may potentially trigger MDS/CMML, they may also be in some cases the consequences of MDS/CMML, when some cells of the immune system are part of the MDS/CMML clone [1, 11] . In addition to its direct pro-apoptotic activity on MDS cells, Azacitidine also has immunomodulatory functions which could explain at least in part its effect in MDS-related AID. Azacitidine can indeed expand CD4+CD25+/FOXP3+ regulatory T cells which are decreased with impaired suppressive function in many AID [19] .
Azacitidine also increases expression of anti-inflammatory molecules like IFNγ and could inhibit CD4+ T-cells and reduce immune-mediated cytotoxicity [11] . Azacitidine could finally decrease the synthesis of inflammatory cytokines like IL-6 [20] . In some cases, Azacitidine therefore could have a positive immunomodulatory effect, even when it is not active on MDS/CMML.
In conclusion, our results suggest that Azacitidine can improve the control of AID associated to MDS/CMML and allow to reduce steroid dose in most patients with MDS and concurrent AID. Prospective studies are necessary to confirm this beneficial effect and the safety of Azacitidine in AID associated with MDS/CMML. 
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